BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Advanced Bio Surfaces Receives CE Mark For OrthoGlide(TM) Medial Knee Implant


2/16/2006 11:08:31 AM

MINNEAPOLIS, Feb. 15 /PRNewswire/ -- Advanced Bio-Surfaces, Inc. (ABS), an orthopedic implant developer and manufacturer, announced today the company has been notified that its Technical File for the OrthoGlide Medial Knee Implant fulfills the requirements of the European Union's (EU) Medical Device Directive. The notification from the Notified Body, TUV Product Services (Munich), allows Advanced Bio-Surfaces to immediately begin applying the CE mark to the OrthoGlide Medial Knee Implant for sale in the EU.

The cobalt-chrome alloy composition of the innovative OrthoGlide implant has successfully passed functional and safety requirements. In addition, the implant's unique engineering design provides positional stability without the use of rigid fixation methods. The OrthoGlide has a specially contoured geometry which functions to provide an open glide path and allows for the unconstrained motion of the femoral condyle, while requiring less tissue and bone removal than current surgical options.

"Receiving the CE mark is another important milestone for Advanced Bio-Surfaces and the development of the OrthoGlide market. ABS is pleased with its achievement of obtaining FDA clearance to market and the CE mark," said Dr. Jeff Felt, Chairman and CEO of Advanced Bio-Surfaces. "The receipt of the CE mark enables us to offer the OrthoGlide implant to more patients in need of a better option for osteoarthritis."

Dr. Klaus Lehrberger from Munich, Germany said, "With this approval, ABS has made significant progress towards providing international orthopedic surgeons and their patients a better solution." Dr. Lehrberger continued, "For surgeons operating in the EU, the CE Mark is intended to ensure them and their patients of the product's safety."

About Advanced Bio-Surfaces, Inc.

ABS is a privately held company dedicated to the development of innovative joint repair products. The OrthoGlide Medial Knee Implant is the company's first product and is intended for treatment of patients with moderate osteoarthritis of the medial compartment. For additional information contact Robert Siegfried at 952.912.5400.

Advanced Bio-Surfaces, Inc.

CONTACT: Robert Siegfried, VP, Finance and Administration, of AdvancedBio-Surfaces, Inc., +1-952-912-5400



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES